The FDA approved a new subcutaneous starting dose of Leqembi (lecanemab-irmb) on July 13, 2026, letting some people with early Alzheimer's begin treatment with at-home injections instead of starting with IV infusions, according to the FDA's approval notice. The approval covers how the drug is given, not a new drug or a broader group of eligible patients. The product is called Leqembi Iqlik, and it's built around a 500 mg weekly dose split into two 250 mg autoinjector shots, each taking about 15 seconds to administer into the abdomen, thigh, or upper arm, per Eisai and BioArctic's announcement. For people with mild cognitive impairment due to Alzheimer's, the practical change is fewer infusion-center visits early in treatment — not a different standard for who qualifies or how well the drug works.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official guidance from FDA — Use this primary source to verify the official guidance.
- Read the official guidance from Bioarctic — Use this primary source to verify the official guidance.
Table of Contents
- What Changed, and What Didn't
- The Safety Requirements That Don't Change With the Route
- Who Actually Administers the First Doses
- When This Becomes Available
- How to Read the Headline Before Asking a Doctor About It
- Frequently Asked Questions
What Changed, and What Didn't
Before this approval, subcutaneous Leqembi existed only as a maintenance option — a 360 mg weekly injection available after a patient had already completed 18 months of IV infusions, according to the Alzheimer's Association. The July 2026 approval is the first to let patients use the subcutaneous route from their very first dose, skipping the IV-only start entirely. What stayed the same is the population the drug treats. The indication covers adults with mild cognitive impairment or mild dementia due to Alzheimer's disease — the identical early-stage group already covered under Leqembi's original IV label, per the Eisai/BioArctic release.
Nobody with moderate or late-stage Alzheimer's gained access through this approval, and the underlying diagnostic requirements for starting treatment did not loosen. The scientific basis for the new starting dose also differs from what many news summaries imply. Regulators didn't require a new efficacy trial measuring cognitive outcomes for the subcutaneous starting regimen. Instead, the approval rested on pharmacokinetic sub-studies within the Phase 3 Clarity AD open-label extension, which showed that weekly subcutaneous dosing produces drug exposure comparable to the IV regimen, according to the Medical Letter on Drugs and Therapeutics. In short: the agency confirmed the body absorbs a similar amount of drug either way, not that the subcutaneous start produces a new clinical benefit.
The Safety Requirements That Don't Change With the Route
Leqembi's label carries a Boxed Warning — the FDA's strongest safety warning — for ARIA, or amyloid-related imaging abnormalities, a type of brain swelling or microbleed that can occur with this class of drug. Patients who carry two copies of the ApoE ε4 gene variant have a higher rate of symptomatic, serious, and severe ARIA, which is why the label calls for ApoE ε4 genotype testing before anyone starts treatment, per the FDA label. That genetic test applies regardless of whether a patient starts by IV or by injection.
The same label also calls for enhanced clinical vigilance during the first 14 weeks of treatment, meaning the MRI monitoring schedule used to catch ARIA early does not shrink just because dosing happens at home. A patient choosing the subcutaneous start still needs the same imaging check-ins during that early window. This matters for how to read the "at-home" framing in headlines. The convenience applies to the injection step itself — avoiding a chair-and-IV-pole visit — not to the surveillance that keeps patients safe during the highest-risk early months of treatment.
Who Actually Administers the First Doses
Self-injection is not unsupervised from day one. For at least the first two doses, a health care provider must guide the administration, and patients are checked in with over time to confirm that at-home dosing remains appropriate for them, according to the Alzheimer's Association.
In practice, that likely means an initial visit or supervised session before a patient or caregiver handles the autoinjector independently. The checked-in model also means a clinician can pull a patient back to in-office administration or closer monitoring if something about their response changes.
When This Becomes Available
Eisai and BioArctic, the companies that developed and market lecanemab, planned a U.S. launch of the day-one subcutaneous starting dose for late August 2026, following the July 13 approval, per their joint announcement. Patients and caregivers asking a prescriber about switching to the at-home start should expect that timeline to govern when it's actually offered, rather than the approval date itself.
How to Read the Headline Before Asking a Doctor About It
The most useful way to frame this news for a prescriber conversation is narrow and specific: this is about where and how the drug is given, not a new efficacy claim or a wider diagnostic net, according to the FDA. Amyloid confirmation and ARIA risk assessment still gate who can start treatment, exactly as under the original IV label. A few questions worth bringing to that conversation:.
- Has ApoE ε4 genotype testing already been done, or does it need to happen before a starting dose of either kind?
- What does the MRI monitoring schedule look like during the first 14 weeks, regardless of IV or subcutaneous start?
- How many supervised doses will happen in-office before self-injection at home becomes an option?
- Is the subcutaneous starting dose available yet, given the companies' planned late-August 2026 rollout?
Frequently Asked Questions
Does the subcutaneous starting dose work differently than the IV version?
No new efficacy trial measured cognitive outcomes for it. Approval relied on pharmacokinetic data from the Clarity AD open-label extension showing comparable drug exposure between the two routes.
Does starting with injections mean less MRI monitoring?
No. Enhanced vigilance for ARIA during the first 14 weeks applies regardless of whether a patient starts by IV or subcutaneous injection.
Can a newly diagnosed patient self-inject from the first dose with no supervision?
No. A health care provider must guide at least the first two doses, and patients are checked in with over time before dosing is handled independently at home.
You Might Also Like
- Tauklarify Tau PET vs Alzheimer’s Blood Tests in 2026: How People With Mild Cognitive Impairment Can Compare Testing Options
- Tauklarify Imaging for Alzheimer’s Tau Tangles in 2026: How People With Mild Cognitive Impairment Can Compare Testing Options
- PrecivityAD2 and Younger-Onset Alzheimer’s Diagnosis in 2026: How People With Mild Cognitive Impairment Can Compare Testing Options
